Pharmacol Biochem Behav. 1991 Nov;40(3):701-8.

Controlled clinical trial of cannabidiol in Huntington's disease.

Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, Kennedy K, Schram K.

Source

Department of Pharmacology/Toxicology, University of Arizona, Tucson 85721.

Abstract

Based on encouraging preliminary findings, cannabidiol (CBD), a major nonpsychotropic constituent of Cannabis, was evaluated for symptomatic efficacy and safety in 15 neuroleptic-free patients with Huntington's Disease (HD). The effects of oral CBD (10 mg/kg/day for 6 weeks) and placebo (sesame oil for 6 weeks) were ascertained weekly under a double-blind, randomized cross-over design. A comparison of the effects of CBD and placebo on chorea severity and other therapeutic outcome variables, and on a Cannabis side effect inventory, clinical lab tests and other safety outcome variables, indicated no significant (p greater than 0.05) or clinically important differences. Correspondingly, plasma levels of CBD were assayed by GC/MS, and the weekly levels (mean range of 5.9 to 11.2 ng/ml) did not differ significantly over the 6 weeks of CBD administration. In summary, CBD, at an average daily dose of about 700 mg/day for 6 weeks, was neither symptomatically effective nor toxic, relative to placebo, in neuroleptic-free patients with HD.

PMID:: 1839644; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Supplemental Content

Save items

Related citations in PubMed

Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans. [Pharmacol Biochem Behav. 1991]
Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans.
Consroe P, Kennedy K, Schram K. Pharmacol Biochem Behav. 1991 Nov; 40(3):517-22.
Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract. [Ther Drug Monit. 2005]
Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
Nadulski T, Pragst F, Weinberg G, Roser P, Schnelle M, Fronk EM, Stadelmann AM. Ther Drug Monit. 2005 Dec; 27(6):799-810.
Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study. [J Neurol Neurosurg Psychiatry....]
Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study.
van Vugt JP, Siesling S, Vergeer M, van der Velde EA, Roos RA. J Neurol Neurosurg Psychiatry. 1997 Jul; 63(1):35-9.
Review Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. [Treat Respir Med. 2004]
Review Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
Keam SJ, Keating GM. Treat Respir Med. 2004; 3(4):247-68.
Review Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD. [Drugs R D. 2003]
Review Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
. Drugs R D. 2003; 4(5):306-9.

See reviews... See all...

Cited by 14 PubMed Central articles

Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol. [PLoS One. 2011]
Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol.
Hegde VL, Nagarkatti PS, Nagarkatti M. PLoS One. 2011 Apr 1; 6(4):e18281. Epub 2011 Apr 1.
Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. [Free Radic Biol Med. 2011]
Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death.
Mukhopadhyay P, Rajesh M, Horváth B, Bátkai S, Park O, Tanchian G, Gao RY, Patel V, Wink DA, Liaudet L, et al. Free Radic Biol Med. 2011 May 15; 50(10):1368-81. Epub 2011 Mar 11.
Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. [J Am Coll Cardiol. 2010]
Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy.
Rajesh M, Mukhopadhyay P, Bátkai S, Patel V, Saito K, Matsumoto S, Kashiwaya Y, Horváth B, Mukhopadhyay B, Becker L, et al. J Am Coll Cardiol. 2010 Dec 14; 56(25):2115-25.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Controlled clinical trial of cannabidiol in Huntington's disease.
Controlled clinical trial of cannabidiol in Huntington's disease.
Pharmacol Biochem Behav. 1991 Nov ;40(3):701-8.

PubMed
Endovascular and open approaches to non-thrombosed popliteal aneurysm repair: a ...
Endovascular and open approaches to non-thrombosed popliteal aneurysm repair: a meta-analysis.
Eur J Vasc Endovasc Surg. 2008 Jul ;36(1):96-100. Epub 2008 Apr 8 .

PubMed
Could cytokines levels or adhesion molecules expression be predictor of IFN-beta...
Could cytokines levels or adhesion molecules expression be predictor of IFN-beta treatment response in multiple sclerosis patients?
Clin Neurol Neurosurg. 2008 Nov ;110(9):947-50. Epub 2008 Apr 8 .

PubMed
Three-dimensional extracellular matrix-directed cardioprogenitor differentiation...
Three-dimensional extracellular matrix-directed cardioprogenitor differentiation: systematic modulation of a synthetic cell-responsive PEG-hydrogel.
Biomaterials. 2008 Jun ;29(18):2757-66. Epub 2008 Apr 7 .

PubMed
Salubrious effect of Kalpaamruthaa, a modified indigenous preparation in adjuvan...
Salubrious effect of Kalpaamruthaa, a modified indigenous preparation in adjuvant-induced arthritis in rats--a biochemical approach.
Chem Biol Interact. 2008 May 28 ;173(2):148-58. Epub 2008 Feb 26 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Controlled clinical trial of cannabidiol in Huntington's disease.

Source

Abstract

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Grant Support

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Cited by 14 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information